Phenamacril is a reversible and non-competitive inhibitor of Fusarium class I myosin

## Rasmus Dam Wollenberg<sup>‡1</sup>, Manuel H. Taft<sup>§1</sup>, Sven Giese<sup>§</sup>, Claudia Thiel<sup> $\Psi$ </sup>, Zoltán Balázs<sup>‡</sup>, Henriette Giese<sup>‡</sup>, Dietmar J. Manstein<sup>§ $\Psi$ </sup>\* and Teis Esben Sondergaard<sup>‡</sup>\*

From the <sup>‡</sup>Department of Chemistry and Bioscience, Aalborg University, DK-9220 Aalborg, Denmark; <sup>§</sup>Institute for Biophysical Chemistry, OE4350, Hannover Medical School, 30623 Hannover, Germany; <sup>Ψ</sup>Division of Structural Biochemistry, OE8830, Hannover Medical School, 30623 Hannover, Germany

## Running title: Inhibition of Fusarium class I myosin by phenamacril

<sup>1</sup>Both authors contributed equally to this work.

\*To whom correspondence should be addressed: Teis Esben Sondergaard, Department of Chemistry and Bioscience, Aalborg University, DK-9220 Aalborg, Denmark; E-mail: <u>tes@bio.aau.dk</u>; Tel. +45 9940 8524; Dietmar J. Manstein, Institute for Biophysical Chemistry, OE4350, Hannover Medical School, 30623 Hannover, Germany; E-mail <u>manstein.dietmar@mh-hannover.de</u>; Tel. +49 511 532 3700 List of supplementary information: Table S1, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5

**Table S1.** Oligo DNA primers used to amplify the regions encoding *Fusarium* calmodulin and myosin class I motor domain constructs. Fg: *Fusarium graminearum*, Fa: *F. avenaceum*, Fs: *F. solani*, CaM: calmodulin, LIC: ligase independent cloning.

Primer	Secure 5' 2'	Targatlagus	Ductoin
ID	Sequence 5 -5	Target locus	1 rotem
P1152	TTTCTCGAGATGGGCCGACTCACTTACTGAAG	FGSG_01891	FgCaM
P1153	GTTTGCTAGCTTATTTTTGCATCATAAGCTGG	FGSG_01891	FgCaM
P1125	GAAGGATCCATGGATTACAAGGATGACGACG	FGSG_01409	FgMyo1
	ATAAGATGGGAATATCGAGACGCCCGAA		
P1126	CCCAAGCTTTTAGTGGTGGTGGTGGTGGTGTG	FGSG_01409	FgMyo1
	AACCTGATCGCATGTGCTCCAGAGCGAA		
P1125	GAAGGATCCATGGATTACAAGGATGACGACG	FGSG_01409	$FgMyo1_{IQ2}$
	ATAAGATGGGAATATCGAGACGCCCGAA		
P1127	CCCAAGCTTTTAGTGGTGGTGGTGGTGGTGTG	FGSG_01409	FgMyo1 <sub>IQ2</sub>
	AACCTGAGTCACGAAGCTGGAGAAATTC		
P1130	GAAGGATCCATGGATTACAAGGATGACGACGA	FAVG1_11042	FaMyo1 <sub>IQ2</sub>
	TAAGATGGGAATATCGAGACGCCCTAA		
P1132	CCCAAGCTTTTAGTGGTGGTGGTGGTGGTGGTGA	FAVG1_11042	$FaMyo1_{IQ2}$
	ACCTGAGTCCCGGAGTTGCAGATACT		
P1135	GAAGGATCCATGGATTACAAGGATGACGACG	NECHADRAFT_10	$FsMyo1_{IQ2}$
	ATAAGATGGGAATATCAAGACGTCCCAA	3022	
P1137	CCCAAGCTTTTAGTGGTGGTGGTGGTGGTGTG	NECHADRAFT_10	$FsMyo1_{IQ2}$
	AACCTGAATCTCGAAGCTGCAAGTACTCG	3022	
P1345	AAAACCTCTATTTTCAGGCCGACTCACTTACT	FGSG_01891	$FgCaM_{LIC}$
	GAAGAG		
P1346	TATCCACCTTTACTGTTATTTTTGCATCATAAG	FGSG_01891	FgCaM <sub>LIC</sub>
	CTGG		



**Figure S1**. Coomassie-Brilliant Blue stained polyacrylamide gels showing two representative fractions resulting from the size-exclusion chromatographic purification of (**A**) FgMyo1<sub>IQ2</sub> co-expressed with calmodulin from *F. graminearum* PH-1 in *Sf*9 insect cells. White line indicates removed lanes. (**B**) *E. coli* BL21(DE3) produced calmodulin from *F. graminearum* PH-1 (FgCaM). Red arrows serve to highlight the presence of the relevant protein-bands.



**Figure S2.** Eadie-Hofstee plots of Phenamacril inhibition of basal ATP turnover in the presence of  $Ca^{2+}$  by FgMyo1. A least-squares regression analysis was used to determine the Eadie-Hofstee linear correlations. Measurements were performed in the presence of 0 ( $\circ$ ), 0.6 ( $\Delta$ ) and 10  $\mu$ M ( $\Box$ ) Phenamacril. Error bars represent standard deviations around the mean (n = 3).



**Figure S3.** Phenamacril docks into the actin-binding groove of the *F. graminearum* class I myosin motor domain (**A**) Position of Phenamacril within the docked homology model of the *F. graminearum* class I myosin motor domain. For reference, the position of the nucleotide binding-pocket is indicated by the position of ADP-vanadate (**B**) Close-up view, highlighting the protein-ligand interactions between Phenamacril (shown as red ball-and-stick model) and amino acid residues from the motor domain (stick-model). Hydrogen-bonds are shown as dotted yellow lines.



**Figure S4.** (A) Pairwise alignment of the class I myosin motor domains from *F. graminearum* PH-1 (FgMyo1), *F. solani* f. sp. *pisi* 77-14-4 (FsMyo1). Amino acids are colored by polarity, dots indicating residues that are conserved in comparison to the reference sequence of FgMyo1. (B) Pre-power stroke homology model of FsMyo1. The molecular surfaces highlighted in yellow (FsMyo1) correspond to the amino acid residues that differ from FgMyo1. (C) Surface-rendering of the Phenamacril docking-pose (red surface) and residues Met375 and S217 (green surfaces). (D) Substitutions S217T and M375K (both present in *F. solani*) in the model of FgMyo1 results in overlap of the volumes enclosed by the red (Phenamacril) and green surface areas.

Fg myosin 1	3	5
Fa myosin 1		15
Fs myosin 1	3	9
Dd myosin 1E		j .
Dd myosin 1B	6	;
Dd myosin 2	MNPIHDRTSDYHKYLKVKQGDSDLFKLTVSDK.YIWYNPDPKER.SYEC.EIVSETSDSF.F.TVDGQDRQVKKDDAN 7	8
Hs myosin 1c	4 A A A A A A A A A A A A A A A A A A A	3
Fa myosin 1	***** KE LGVSDI TI L * SKVSNEA INENI KKREEGRE LYTY I GHVI VSVNPERDI G LYTDDVI OSYMGKNRI EMPPHV 1	07
Ea myosin 1		07
Es myosin 1	A 0 D K 1	11
Dd myosin 1E	AF P FV NOITEN FL TM HKSDN D VI T KN N KESDIKA N RYKY I 7	7
Dd myosin 1B	AKO TD VM -P EDE C VMNDE N P I N NNSCO FIEA P HAO V 7	8
Dd myosin 2	ORNEL ED E MSE - VINEP VEH RV YNODI SIE A KRIP OFMVDIEK RR N VA I 1	55
He myosin 1c	DRV O EV ENET EA EL DR RENI D Y O SPOHMER VS V I 1	16
		10
Fg myosin 1	FAIAEASYYNMKAYSDNQCVIISGESGAGKTEAAKRIMQYIASVSGGESGD-IKQIKDMVLATNPLLESFGNAKTLRN 1	84
Fa myosin 1	· · · · · · · · · · · · · · · · · · ·	84
Fs myosin 1	SA 1	88
Dd myosin 1E	Y.L.NDA.RS.RQSQE	54
Dd myosin 1B	YQL. SA.RA. NDQE	54
Dd myosin 2	SDVA.RS.LDDRQSLL.TNT.KVI.LA.RNQANGSGVLEQQI.QAIA	.33
Hs myosin 1c		92
Fg myosin 1	NNSSRFGKYLQIYFNTQGEPVGADITNYLLEKSRVVGQITNERNFHIFYQFAKGASQQYRETFGVQ-KPETYVYTSRS 2	61
Fa myosin 1		61
Fs myosin 1	A	65
Dd myosin 1E	DMEMQ.AV.S.I.GKRTQG.SML.L.SKLNEL.LTPNAPA.E.LKK.2	32
Dd myosin 1B	FE.Q.DKA.D., GK.Y	31
Dd myosin 2		10
Hs myosin 1c	DMDVQ.DFK.AGH.LSH.NHGLLE.GEEETLRRL.LERN.QS.L.LVKG 2	270
Fa myosin 1	KCLDVDGLDDLAEFEDTLNAMKVIGLSOPEODOLERMISALIWIGNLOFOEDOGGYAEVTDRSVVDFAAVLME 3	34
Fa myosin 1		34
Es myosin 1		38
Dd myosin 1F	G F ST SG KILVK ETI KESD NS W I A H T A AAFORTGTTVK S TKSIAA SCIK 3	10
Dd myosin 1B	O YT N VSDVAEVRO DT TAO SD L IVACV H Y L DK N	04
Dd myosin 2	G V LK VS SE KL RO DIV F F MS KLIAG HI K FKGA FG	183
Hs myosin 1c	O AK SS N KSDWKVVRK IT DETED VEDILSIVASV HI H AANEESNO TENOLKVITE IS 3	43
Fg myosin 1	VTPDQLIKGITIRILTPRNGEVIESPANPAQAQATRDALAMATYSNLFDWIVERINKSLKARQPT3	99
Fa myosin 1	E	.99
Es myosin 1		03
Dd myosin 1E	TDQQS.STALCY.STSTGVKRCS.SV.MDCKAYSKL.ER.N.L.SK.TTINCTTEKG3	08
Da myosin 1B	IDSAT. QNA. LF. VINIGGAGGA. NRRSTINV.Q. VE. NG	11
Dd myosin 2	N.SV.E.ALMEPRILAGRDLVAQHL.VERSSSSVK.L.GR.LLL.KK.NV.G-QE.KA4	41
Hs myosin 1c	EGST.REAL.H.KITAKGELL.L.LE. AYAK.V. RT.T.L.GK. R. ASKDVES.SWRS 4	13
Fg myosin 1	TNTIGILDIYGFEIFEKNSFEQLCINYVNEKLQQIFIQLTLKAEQEEYAREQIQWTPIKY-FDNKVVCDLIEQIRPVG 4	76
Fa myosin 1	· · · · · · · · · · · · · · · · · · ·	76
Fs myosin 1	SD. K	80
Dd myosin 1E	VV.QN	54
Dd myosin 1B	Q.VF	54
Dd myosin 2	-YF. V S	24
Hs myosin 1c	TVL.LV.QHFCL.ESEA.G.A.E.VQN.IIVEKFK. 4	89
Fg myosin 1	IFSAMKDATKTAHADPAACDRTFMQSINGMSHAHLTPRQGNFIIKHYAGDVTYTVEGITDKNKD 5	i40
Fa myosin 1		40
Fs myosin 1		44
Dd myosin 1E	LI.LLDE.CLIAKST.Q.,LDCKQFEKNPHLQSYVVSKDRSIGDTC.RLD.R.FL5	25
Dd myosin 1B	LLD.ICS.LQSTGT.QK.LEKMA.IYDGHW.GMT.A.AEEAFS5	20
Dd myosin 2	.LALLDEQSVFN.T.N.LITKLS.FSKKNAKYEEPRFSKTE.GVTQ.M.EIQDWLE5	90
Hs myosin 1c	.I.ILDEECLRPGE.T.LLEKLEDTVKH.PHFLTHKLADQRTRKSLGR.E.RLLES.T.FLN.5	64
Fg myosin 1	QLLKGLLALFQHSGNDFVHTLFPRPVDTDNRKQPP SAGDRIRASANALVDTLMKCQPSYIRTIKPNENKSPTEYN 6	15
Fa myosin 1		15
Fs myosin 1	NQQ	19
Dd myosin 1E	T.FGD. ISSM.S.SDPL.QGPTRPE.SK.R.ET., SQF.NAMIT.LA.S.H.V.CS.D. QAGVID 6	00
Od myosin 1B	T. FFD. IEAI.C. KMP. LAS NEDTGSLQK.R.TT FK.KT GE.MKA.SQ.T.HCT.KAKDWE 5	95
Dd myosin 2	P.QQD.ELC.KD.SDNV.TKND.NIASRA.KGANFITVAAQYKEQLAS.MAETTN.HFV.C.INKQL.AKLE 6	68
Hs myosin 1c	L.FRN.KETMCS.K.PIMSQC.D.SELSK.R.ETVATQFKM.LLQEI.QSKE.A.V.CDA.Q.GRFD 6	38
Fa myosin 1	GPNVLHOLKYLGLOENVRLRRAGFAYRODEDKEVDREFLLSPAT-SYAGEETWEGTTEAAVKOLLKDTSLPKEEWONG 6	92
Fa myosin 1	- K E	92
Es myosin 1	A Y D	96
Dd myosin 1E	EDR.R. VR. L. V. G. LEYTR, YN. YKM, CKK, WPSFN, AKO, TEL, OOHN, D. I.R. 6	73
Dd myosin 1B	NSR.K. VQL. V. NT. VLK.YKK.SK.WGIW K.DAIEGC.T.FQ.MNLEAGO. L. 6	71
Dd myosin 2	DKV. D. LRCN. VL. GI T. K. PN. IIYAD K. YY. A. NV-PRDAEDSOK. TDAV. HLN. DP. OVRF. 7	40
Hs myosin 1c	EVLIR. V L. V RKYEA, LQ. YKS. C. E. WPT A. RPQDG. AVLVRHLGYKP YK. 7	'11
Ea munoir 4		
Fg myosin 1	TINOL FIGHT ALEMIN VALUE ALEMIN VALUE ALEMIN AL	
ra myoshi T		
Fe munein 1	F 740	
Fs myosin 1 Dd myosin 1E	K. V. RN. T. YF. EK. ELEMPRIV. L. KT. G. R. RSKWNO. RKA IK. L	
Fs myosin 1 Dd myosin 1E Dd myosin 1B	K. V. RN.T. YF.EK.ELEMPRIV.L. KT. G.R.RSKWNQ-RKA.IK.L. FY. 730 K. V. RH. V.L. EAL.KKDEDCTAK, KAF.N. K709	
Fs myosin 1 Dd myosin 1E Dd myosin 1B Dd myosin 2	K. V. RN.T. YF.EK.ELEMPRIV.L. KT. G.R.RSKWNQ-RKA.IK.L.F. 749 K. V. RH. V.L. EAL.KKDFDCTAK. KAF.N. K709 I. I. FR.GO. ARI.EA.EQRISELIKA. AAT.GWI.RKVYKOAR.HTVAARIIOONLRAVIDEKSWPW K 812	
Fs myosin 1 Dd myosin 1E Dd myosin 1B Dd myosin 2 Hs myosin 1c	K. V. RN.T. YF.EK.ELEMPRIV.L. KT. G.R.RSKWNQ-RKA.IK.L. F. 749 K. V. RH. V.L. EAL.KKDFDCTAK. KAF.N. K. I. FR.GQ-ARI.EA.EQRISEIIKA. AAT.GWI.RKVYKQAR.HTVAARIIQQNLRAYIDFKSWPW.K 812 R. I. RF.K. T.DALEVRQSL.K. AA. GFHWRQKFLRVKR.IC.S. W. 769	

**Figure S5.** Multiple sequence alignment of the motor domain constructs used in this study. Fg: *Fusarium graminearum*, Fa: *F. avenaceum*, Fs: *F. solani*, Dd: *Dictyostelium discoideum*, Hs: *Homo sapiens*. Positions of amino acid residues implicated in mutation-induced Phenamacril-resistance in *F. graminearum* are shown in red boxes. Amino acids substitutions are highlighted as red dots.